S3 show the results for the outcome MACE: both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk for MACE (13% and 11%, respectively) as compared with placebo, and a lower risk for MACE as compared with DPP-4 inhibitors (12% and 11%, respectively)
Most providers start you at 2.5 mg of tirzepatide, regardless of what semaglutide dose you were taking
Adjust supplementation based on results rather than symptoms alone
- L-
[DOI] [PubMed] [Google Scholar] 99.Shinozaki S., Chang K., Sakai M., Shimizu N., Yamada M., Tanaka T., Nakazawa H., Ichinose F., Yamada Y., Ishigami A., et al
L-arginine has long been used in the enhancement of sports performance and cardiac function